Repaglinide (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Repaglinide" in Italian language version.

refsWebsite

Global rank Italian rank

15nih.gov

4^th place

9^th place

10doi.org

2^nd place

7^th place

5oadoi.org

799^th place

22^nd place

5archive.org

6^th place

8^th place

1diabetesjournals.org

low place

1fda.gov

447^th place

644^th place

archive.org

MS. Thomsen, D. Chassard; E. Evène; KK. Nielsen; M. Jørgensen, Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects., in J Clin Pharmacol, vol. 43, n. 1, gennaio 2003, pp. 23-8, PMID 12520624.
M. Niemi, PJ. Neuvonen; KT. Kivistö, The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide., in Clin Pharmacol Ther, vol. 70, n. 1, luglio 2001, pp. 58-65, DOI:10.1067/mcp.2001.116511, PMID 11452245.
M. Khamaisi, E. Leitersdorf, Severe hypoglycemia from clarithromycin-repaglinide drug interaction., in Pharmacotherapy, vol. 28, n. 5, maggio 2008, pp. 682-4, DOI:10.1592/phco.28.5.682, PMID 18447665.
M. Niemi, JT. Backman; M. Neuvonen; PJ. Neuvonen; KT. Kivistö, Rifampin decreases the plasma concentrations and effects of repaglinide., in Clin Pharmacol Ther, vol. 68, n. 5, novembre 2000, pp. 495-500, DOI:10.1067/mcp.2000.111183, PMID 11103752.
LI. Kajosaari, M. Niemi; M. Neuvonen; J. Laitila; PJ. Neuvonen; JT. Backman, Cyclosporine markedly raises the plasma concentrations of repaglinide., in Clin Pharmacol Ther, vol. 78, n. 4, ottobre 2005, pp. 388-99, DOI:10.1016/j.clpt.2005.07.005, PMID 16198658.

diabetesjournals.org

care.diabetesjournals.org

(EN) Julio Rosenstock, David R. Hassman e Robert D. Madder, Repaglinide Versus Nateglinide Monotherapy: A randomized, multicenter study, in Diabetes Care, vol. 27, n. 6, 1º giugno 2004, pp. 1265–1270, DOI:10.2337/diacare.27.6.1265. URL consultato il 27 novembre 2019.

doi.org

dx.doi.org

DR. Owens, Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs., in Diabet Med, 15 Suppl 4, 1998, pp. S28-36, DOI:10.1002/(SICI)1096-9136(1998120)15:4+S28::AID-DIA7483.0.CO;2-T, PMID 9868989.
V. Hatorp, WC. Huang; P. Strange, Repaglinide pharmacokinetics in healthy young adult and elderly subjects., in Clin Ther, vol. 21, n. 4, aprile 1999, pp. 702-10, DOI:10.1016/S0149-2918(00)88321-6, PMID 10363735.
(EN) Julio Rosenstock, David R. Hassman e Robert D. Madder, Repaglinide Versus Nateglinide Monotherapy: A randomized, multicenter study, in Diabetes Care, vol. 27, n. 6, 1º giugno 2004, pp. 1265–1270, DOI:10.2337/diacare.27.6.1265. URL consultato il 27 novembre 2019.
M. Niemi, PJ. Neuvonen; KT. Kivistö, The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide., in Clin Pharmacol Ther, vol. 70, n. 1, luglio 2001, pp. 58-65, DOI:10.1067/mcp.2001.116511, PMID 11452245.
M. Khamaisi, E. Leitersdorf, Severe hypoglycemia from clarithromycin-repaglinide drug interaction., in Pharmacotherapy, vol. 28, n. 5, maggio 2008, pp. 682-4, DOI:10.1592/phco.28.5.682, PMID 18447665.
M. Niemi, JT. Backman; M. Neuvonen; PJ. Neuvonen; KT. Kivistö, Rifampin decreases the plasma concentrations and effects of repaglinide., in Clin Pharmacol Ther, vol. 68, n. 5, novembre 2000, pp. 495-500, DOI:10.1067/mcp.2000.111183, PMID 11103752.
LI. Kajosaari, J. Laitila; PJ. Neuvonen; JT. Backman, Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin., in Basic Clin Pharmacol Toxicol, vol. 97, n. 4, ottobre 2005, pp. 249-56, DOI:10.1111/j.1742-7843.2005.pto_157.x, PMID 16176562.
T. Kudo, A. Hisaka; Y. Sugiyama; K. Ito, Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes., in Drug Metab Dispos, vol. 41, n. 2, febbraio 2013, pp. 362-71, DOI:10.1124/dmd.112.049460, PMID 23139378.
LI. Kajosaari, M. Niemi; M. Neuvonen; J. Laitila; PJ. Neuvonen; JT. Backman, Cyclosporine markedly raises the plasma concentrations of repaglinide., in Clin Pharmacol Ther, vol. 78, n. 4, ottobre 2005, pp. 388-99, DOI:10.1016/j.clpt.2005.07.005, PMID 16198658.
JT. Backman, LI. Kajosaari; M. Niemi; PJ. Neuvonen, Cyclosporine A increases plasma concentrations and effects of repaglinide., in Am J Transplant, vol. 6, n. 9, settembre 2006, pp. 2221-2, DOI:10.1111/j.1600-6143.2006.01456.x, PMID 16869799.

fda.gov

Onyeka Otugo, Olabode Ogundare, Christopher Vaughan, Emmanuel Fadiran, Leyla Sahin, Consistency of Pregnancy Labeling Across Different Therapeutic Classes (PDF), su fda.gov, Food and Drug Administration - Office of Women’s Health, 1979. URL consultato il 27 giugno 2013.

nih.gov

ncbi.nlm.nih.gov

DR. Owens, Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs., in Diabet Med, 15 Suppl 4, 1998, pp. S28-36, DOI:10.1002/(SICI)1096-9136(1998120)15:4+S28::AID-DIA7483.0.CO;2-T, PMID 9868989.
V. Hatorp, S. Oliver; CA. Su, Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers., in Int J Clin Pharmacol Ther, vol. 36, n. 12, dicembre 1998, pp. 636-41, PMID 9877000.
V. Hatorp, Clinical pharmacokinetics and pharmacodynamics of repaglinide., in Clin Pharmacokinet, vol. 41, n. 7, 2002, pp. 471-83, PMID 12083976.
V. Hatorp, WC. Huang; P. Strange, Repaglinide pharmacokinetics in healthy young adult and elderly subjects., in Clin Ther, vol. 21, n. 4, aprile 1999, pp. 702-10, DOI:10.1016/S0149-2918(00)88321-6, PMID 10363735.
V. Hatorp, WC. Huang; P. Strange, Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes., in J Clin Endocrinol Metab, vol. 84, n. 4, aprile 1999, pp. 1475-8, PMID 10199798.
MS. Thomsen, D. Chassard; E. Evène; KK. Nielsen; M. Jørgensen, Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects., in J Clin Pharmacol, vol. 43, n. 1, gennaio 2003, pp. 23-8, PMID 12520624.
R. Sannerstedt, P. Lundborg; BR. Danielsson; I. Kihlström; G. Alván; B. Prame; E. Ridley, Drugs during pregnancy: an issue of risk classification and information to prescribers., in Drug Saf, vol. 14, n. 2, febbraio 1996, pp. 69-77, PMID 8852521.
AJ. Scheen, Drug interactions of clinical importance with antihyperglycaemic agents: an update., in Drug Saf, vol. 28, n. 7, 2005, pp. 601-31, PMID 15963007.
M. Niemi, PJ. Neuvonen; KT. Kivistö, The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide., in Clin Pharmacol Ther, vol. 70, n. 1, luglio 2001, pp. 58-65, DOI:10.1067/mcp.2001.116511, PMID 11452245.
M. Khamaisi, E. Leitersdorf, Severe hypoglycemia from clarithromycin-repaglinide drug interaction., in Pharmacotherapy, vol. 28, n. 5, maggio 2008, pp. 682-4, DOI:10.1592/phco.28.5.682, PMID 18447665.
M. Niemi, JT. Backman; M. Neuvonen; PJ. Neuvonen; KT. Kivistö, Rifampin decreases the plasma concentrations and effects of repaglinide., in Clin Pharmacol Ther, vol. 68, n. 5, novembre 2000, pp. 495-500, DOI:10.1067/mcp.2000.111183, PMID 11103752.
LI. Kajosaari, J. Laitila; PJ. Neuvonen; JT. Backman, Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin., in Basic Clin Pharmacol Toxicol, vol. 97, n. 4, ottobre 2005, pp. 249-56, DOI:10.1111/j.1742-7843.2005.pto_157.x, PMID 16176562.
T. Kudo, A. Hisaka; Y. Sugiyama; K. Ito, Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes., in Drug Metab Dispos, vol. 41, n. 2, febbraio 2013, pp. 362-71, DOI:10.1124/dmd.112.049460, PMID 23139378.
LI. Kajosaari, M. Niemi; M. Neuvonen; J. Laitila; PJ. Neuvonen; JT. Backman, Cyclosporine markedly raises the plasma concentrations of repaglinide., in Clin Pharmacol Ther, vol. 78, n. 4, ottobre 2005, pp. 388-99, DOI:10.1016/j.clpt.2005.07.005, PMID 16198658.
JT. Backman, LI. Kajosaari; M. Niemi; PJ. Neuvonen, Cyclosporine A increases plasma concentrations and effects of repaglinide., in Am J Transplant, vol. 6, n. 9, settembre 2006, pp. 2221-2, DOI:10.1111/j.1600-6143.2006.01456.x, PMID 16869799.

oadoi.org

DR. Owens, Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs., in Diabet Med, 15 Suppl 4, 1998, pp. S28-36, DOI:10.1002/(SICI)1096-9136(1998120)15:4+S28::AID-DIA7483.0.CO;2-T, PMID 9868989.
V. Hatorp, WC. Huang; P. Strange, Repaglinide pharmacokinetics in healthy young adult and elderly subjects., in Clin Ther, vol. 21, n. 4, aprile 1999, pp. 702-10, DOI:10.1016/S0149-2918(00)88321-6, PMID 10363735.
LI. Kajosaari, J. Laitila; PJ. Neuvonen; JT. Backman, Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin., in Basic Clin Pharmacol Toxicol, vol. 97, n. 4, ottobre 2005, pp. 249-56, DOI:10.1111/j.1742-7843.2005.pto_157.x, PMID 16176562.
T. Kudo, A. Hisaka; Y. Sugiyama; K. Ito, Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes., in Drug Metab Dispos, vol. 41, n. 2, febbraio 2013, pp. 362-71, DOI:10.1124/dmd.112.049460, PMID 23139378.
JT. Backman, LI. Kajosaari; M. Niemi; PJ. Neuvonen, Cyclosporine A increases plasma concentrations and effects of repaglinide., in Am J Transplant, vol. 6, n. 9, settembre 2006, pp. 2221-2, DOI:10.1111/j.1600-6143.2006.01456.x, PMID 16869799.